This proposal represents a request for continued funding of the NIH-sponsored Clinical Pharmacology Fellowship Training Program at the Mayo Clinic-Mayo Clinic College of Medicine-Mayo Medical School. The foundation for this program is strong research training in state-of-the-art biomedical techniques as applied to human-drug interactions. The Mayo Clinical Pharmacology training experience includes a curriculum that systematically exposes Trainees to critical aspects of the science that underlies Clinical Pharmacology. At the heart of the training is an outstanding individual research experience within a supportive mentoring environment. Clinical Pharmacology is a "bridge discipline" devoted to the study of the interaction between drugs and biological systems. However, within the context of the ongoing "revolution" that is occurring in biomedical science, a revolution that promises to transform medical practice, Clinical Pharmacology lies at the confluence of molecular pharmacology, genomics, proteomics, bioinformatics and rational therapeutics-with an ultimate goal of truly "individualized" drug therapy. Specifically, Clinical Pharmacology seeks to enhance our understanding of the molecular basis for drug response and the application of that information at the translational interface to make it possible to tailor drug therapy to both he underlying disease process and the unique characteristics of each individual patient. Our ability to take advantage of the opportunity represented by the dramatic advances that are occurring in biomedical science to achieve those goals will require that we train a new generation of Clinical Pharmacologists in "Systems Clinical Pharmacology". Large, comprehensive, integrated academic medical centers like the Mayo Clinic are ideally positioned to train this new generation of Clinical Pharmacologists. Mayo is able to do that because of its long history of the integration of basic and clinical medical research, because of a tradition of continuous contribution to the discipline of Clinical Pharmacology and because the Mayo Clinical Pharmacology Training Program has had decades of experience in successfully recruiting and training both physician scientists and laboratory-based translational scientists in Clinical Pharmacology. During the next funding cycle, the Mayo Clinical Pharmacology Fellowship Training Program will continue to emphasize strong laboratory-based research training in a supportive mentored environment joined with systematic exposure to developments in clinical science, with an emphasis on the rapidly evolving nature of biomedical science-all directed toward the goal of preparing each Fellow enrolled in the Program to become a future leader in Clinical Pharmacology.

Public Health Relevance

This proposal is a request for continued funding of the NIH-sponsored Clinical Pharmacology Fellowship Training Program at the Mayo Clinic. Clinical Pharmacology is a bridge discipline that lies at the confluence of molecular pharmacology, genomics, bioinformatics and rational therapeutics-with the ultimate goal of truly individualized drug therapy.

Agency
National Institute of Health (NIH)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008685-17
Application #
8689069
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chaudhuri, Leena; Vincelette, Nicole D; Koh, Brian D et al. (2014) CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica 99:688-96
Monte, Andrew A; Heard, Kennon J; Campbell, Jenny et al. (2014) The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med 21:879-85
Matimba, Alice; Li, Fang; Livshits, Alina et al. (2014) Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics 15:433-47
Berg, Alexander K; Mandrekar, Sumithra J; Ziegler, Katie L Allen et al. (2013) Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. J Clin Pharmacol 53:403-12
Austin, Susan A; d'Uscio, Livius V; Katusic, Zvonimir S (2013) Supplementation of nitric oxide attenuates AýýPP and BACE1 protein in cerebral microcirculation of eNOS-deficient mice. J Alzheimers Dis 33:29-33
Chen, Yuhong; Snyder, Melissa R; Zhu, Yi et al. (2011) Simultaneous phenotyping and quantification of ?-1-antitrypsin by liquid chromatography-tandem mass spectrometry. Clin Chem 57:1161-8
Rudin, Dan; Li, Liang; Niu, Nifang et al. (2011) Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination. J Drug Metab Toxicol 2:1-10
Alekseev, Alexey E; Reyes, Santiago; Yamada, Satsuki et al. (2010) Sarcolemmal ATP-sensitive K(+) channels control energy expenditure determining body weight. Cell Metab 11:58-69
Saleem, Umer; Mosley Jr, Thomas H; Kullo, Iftikhar J (2010) Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 30:1474-8
Austin, Susan A; Santhanam, Anantha V; Katusic, Zvonimir S (2010) Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res 107:1498-502

Showing the most recent 10 out of 20 publications